Stewart Paul M, Prescott Stephen M
College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.
J Clin Invest. 2009 Apr;119(4):760-3. doi: 10.1172/jci38936.
COX-2 promotes colon cancer. While both nonselective NSAIDs and selective COX-2 inhibitors reduce disease burden, their adverse gastrointestinal and cardiovascular side effects limit their therapeutic use. In this issue of the JCI, Zhang et al. used gene silencing and a derivative of licorice root to show that inhibition of the enzyme 11beta-hydroxysteroid dehydrogenase type II(11betaHSD2) reduces tumor COX-2 activity, tumor growth, and metastasis by increasing the tonic glucocorticoid-mediated suppression of the COX-2 signaling pathway without the adverse effects associated with NSAIDs and selective COX-2 inhibitors (see the related article beginning on page 876). Their findings suggest that 11betaHSD2 inhibition may be a potential therapeutic option in colon cancer, warranting further investigation.
环氧化酶-2（COX-2）促进结肠癌的发生。非选择性非甾体抗炎药（NSAIDs）和选择性COX-2抑制剂均可减轻疾病负担，但它们的胃肠道和心血管不良副作用限制了其治疗用途。在本期《临床研究杂志》（JCI）中，Zhang等人利用基因沉默和一种甘草根衍生物表明，抑制11β-羟类固醇脱氢酶II型（11βHSD2）可通过增强糖皮质激素对COX-2信号通路的持续性抑制作用来降低肿瘤COX-2活性、肿瘤生长和转移，且无NSAIDs和选择性COX-2抑制剂相关的不良反应（见第876页开始的相关文章）。他们的研究结果表明，抑制11βHSD2可能是结肠癌的一种潜在治疗选择，值得进一步研究。
